Focal Adhesion Kinase (FAK)

Focal Adhesion Kinase (FAK) is a non-receptor tyrosine kinase crucial for cell adhesion, migration, proliferation, and survival. It has four domains: N-terminal FERM (protein interactions, membrane binding), central catalytic kinase (enzymatic activity), proline-rich (SH3 binding sites), and C-terminal FAT (focal adhesion targeting, interacts with paxillin). FAK is autoinhibited in its inactive state through FERM-kinase interaction. Activation involves membrane binding by FERM, conformational change disrupting autoinhibition, autophosphorylation, and Src-mediated phosphorylation. Mechanical forces can also induce activation. FAK localizes primarily to focal adhesions, acting as a hub in signaling pathways regulating cell-matrix interactions and mechanotransduction. It is overexpressed in many cancers, contributing to growth, invasion, metastasis, and drug resistance, making it a therapeutic target. FAK inhibitors are in development and clinical trials for cancer therapy.

FAK inhibitors target the enzymatic activity of FAK, aiming to block downstream signaling pathways involved in cell adhesion, migration, proliferation, survival, and mechanotransduction. This inhibition is intended to suppress tumor growth, invasion, metastasis, and overcome drug resistance in cancer.